FDA approval announcements

GeoVax and Moderna Receive $45M and $176M BARDA Funding for Vaccine Development

Jul 2, 2024, 11:02 AM

GeoVax Labs has advanced its COVID-19 vaccine development with up to $45 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). The funding is part of BARDA's Project NextGen initiative, which has a total of $4.7 billion at its disposal. So far, BARDA has awarded approximately 55% of this amount, with nearly $1.9 billion allocated to new COVID-19 vaccines. Since 2023, BARDA has awarded $2.58 billion in grants, with 73% of the funding directed towards vaccine development. BARDA Director Gary Disbrow highlighted the focus on immunocompromised populations. Additionally, Moderna has received $176 million from the US government to accelerate the development of a pandemic influenza mRNA vaccine, amid concerns over bird flu.